EUVIMEDEUVIMED entdecken
Open Access

Stroke and Bleeding Risks With Non–Vitamin K Oral Anticoagulants in Nonvalvular Atrial Fibrillation

Marie C Bradley, Andrew L Simon, Joy Kolonoski, David J Graham, Rongmei Zhang, John G Connolly

JAMA Network Open · 24.04.2026 · 9 (4) · e269082

DOI: 10.1001/jamanetworkopen.2026.9082 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 24.04.2026. Verfasst von Marie C Bradley und 5 weiteren Autor:innen. Beteiligte Einrichtung: Office of Medical Policy, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland. Hauptthemen laut MEDLINE: Atrial Fibrillation, Stroke, Anticoagulants, Hemorrhage. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance A study using Medicare data concluded that among patients aged 65 years or older, rivaroxaban had a less favorable benefit-harm profile compared with other non–vitamin K oral anticoagulants (NOACs); however, it is unclear whether this finding persists in younger users.

Objective

To compare major extracranial bleeding (MEB), gastrointestinal bleeding (GIB), intracranial hemorrhage (ICH), and thromboembolic stroke in individuals aged younger than 65 years using non–vitamin K oral anticoagulants (NOAC users) for nonvalvular atrial fibrillation (NVAF). Design, Setting, and Participants This cohort study using health care claims data between October 2010 and February 2022 in the FDA Sentinel System included standard dose NOAC (rivaroxaban, apixaban, and dabigatran) users with NVAF aged 21 to 64 years. Analyses conducted between December 2022 and August 2023. Main Outcomes and Measures Hazard ratios (HRs) and 95% CIs were estimated for each outcome (MEB, GIB, ICH, and thromboembolic stroke) in inverse probability of treatment-weighted pairwise comparisons: rivaroxaban vs apixaban, rivaroxaban vs dabigatran, and dabigatran vs apixaban.

Results

A total of more than 173 000 patients (mean [SD] age, 56.6 [7.23] years; 27.5% female; 72.5% male) were included across the 3 exposure cohorts. The number of NOAC users for each pairwise comparison were rivaroxaban (57 932) vs apixaban (96 057), rivaroxaban (57 399) vs dabigatran (20 188), and dabigatran (20 163) vs apixaban (96 668). Rivaroxaban was associated with higher risks of MEB and GIB compared with apixaban (MEB: HR, 1.91; 95% CI, 1.56-2.34; GIB: HR, 1.92, 95% CI, 1.54-2.39), while differences in thromboembolic stroke prevention were not significant (HR, 1.05; 95% CI, 0.77-1.44). Dabigatran was associated with higher thromboembolic stroke risk (rivaroxaban vs dabigatran: HR, 0.61; 95% CI, 0.39-0.94; dabigatran vs apixaban: HR, 1.74; 95% CI, 1.13-2.68). Conclusions and Relevance These findings suggest that for patients aged younger than 65 years treated with NOACs for NVAF, apixaban was associated with the most favorable benefit-harm profile. While the results suggest that rivaroxaban may have provided greater stroke prevention than dabigatran, it was associated with higher bleeding risks than apixaban without additional stroke prevention. The higher thromboembolic stroke risks observed with dabigatran in younger patients suggest important age-related differences in effectiveness that warrant further investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationStrokeAnticoagulantsHemorrhageHumansFemaleMaleMiddle AgedAdultRivaroxabanPyrazolesDabigatranAdministration, OralCohort StudiesUnited StatesPyridonesYoung AdultAged

Substanzen

AnticoagulantsRivaroxabanPyrazolesDabigatranapixabanPyridones

Autor:innen und Institutionen

  • Office of Medical Policy, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.
  • Department of Population Medicine, Harvard Pilgrim Health Care Institute, Boston, Massachusetts.
  • Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.
  • Office of Biostatistics, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.

Zitieren

APA

Bradley, M. C., Simon, A. L., Kolonoski, J., Graham, D. J., Zhang, R., & Connolly, J. G. (2026). Stroke and Bleeding Risks With Non–Vitamin K Oral Anticoagulants in Nonvalvular Atrial Fibrillation. JAMA Network Open, 9(4), e269082. https://doi.org/10.1001/jamanetworkopen.2026.9082

Vancouver

Bradley MC, Simon AL, Kolonoski J, Graham DJ, Zhang R, Connolly JG. Stroke and Bleeding Risks With Non–Vitamin K Oral Anticoagulants in Nonvalvular Atrial Fibrillation. JAMA Network Open. 2026;9(4):e269082. doi:10.1001/jamanetworkopen.2026.9082

BibTeX
@article{Bradley2026,
  author = {Bradley, Marie C and Simon, Andrew L and Kolonoski, Joy and Graham, David J and Zhang, Rongmei and Connolly, John G},
  title = {Stroke and Bleeding Risks With Non–Vitamin K Oral Anticoagulants in Nonvalvular Atrial Fibrillation},
  journal = {JAMA Network Open},
  year = {2026},
  volume = {9},
  number = {4},
  pages = {e269082},
  doi = {10.1001/jamanetworkopen.2026.9082}
}
Kostenlos starten →